Skip to main content
Fig. 1 | Cell Communication and Signaling

Fig. 1

From: Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer

Fig. 1

Molecular mechanisms of 3rd-generation EGFR-TKI (osimertinib) resistance, including EGFR modification (mutation/amplification), alternative pathway activation (MET/HER2/FGFR1 Amp, IGF1R/AXL Act), downstream pathway activation, epithelial-mesenchymal transition (EMT), histological transition, oncogenes fusions and cell cycle gene aberrations. Once EGFR is activated, it will cause multiple downstream signaling cascades activation such as RAS-RAF-MEK-ERK pathway, PI3K/AKT signal pathway, JAK/STAT signal transduction pathway, thus promoting transcriptional activation, cell proliferation, mitosis, anti-apoptosis, invasion and metastasis. act Activation; amp, amplification, del Deletion, mut Mutation

Back to article page

Cell Communication and Signaling

ISSN: 1478-811X